Goldman Sachs Maintains Buy on AbCellera Biologics, Lowers Price Target to $24

Benzinga · 08/04/2023 13:11
Goldman Sachs analyst Andrea Tan maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and lowers the price target from $27 to $24.
Recently
Symbol
Price
%Change